Once-daily fondaparinux monotherapy without warfarin for long-term treatment of venous thromboembolism

• References

• 1 Petitou M, Duchaussoy P, Herbert JM. et al. The synthetic pentasaccharide fondaparinux: first in the class of antithrombotic agents that selectively inhibit coagulation factor Xa. Semin Thromb Hemost 2002; 28: 393-402.
• 2 Sankoh AJ, Huque MF, Dubey SD. Some comments on frequently used multiple endpoint adjustments methods in clinical trials. Statistics Med 1997; 16: 2529-2542.
• 3 Beckman JA, Dunn K, Sasahara AA. et al. Enoxaparin monotherapy without oral anticoagulation to treat acute symptomatic pulmonary embolism. Thromb Haemost 2003; 89: 953-958.
• 4 Kucher N, Quiroz R, Mckean S. et al. Extended enoxaparin monotherapy for acute symptomatic pulmonary embolism. Vascular Med 2005; 10: 251-256.
• 5 Hull RD, Pineo GF, Brant RF. et al. Self-managed long-term low-molecular-weight heparin therapy: the balance of benefits and harms. Am J Med 2007; 120: 72-82.
• 6 Buller HR, Davidson BL, Decousus H. et al. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med 2003; 349: 1695-1702.
• 7 Buller HR, Davidson BL, Decousus H. et al. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Ann Intern Med 2004; 140: 867-873.
• 8 Wittkowsky AK, Downing J, Blackburn J. et al. Warfarin-related outcome in patients with antiphospholipid antibody syndrome managed in an anticoagulation clinic. Thromb Haemost 2006; 96: 137-141.
• 9 Arixtra Dosing and Administration.. GlaxoSmith- Kline. Available at: http://www.arixtra.com/dosing.htm . Accessed March 12, 2007.